Exprivia S.p.A.

BIT:XPR Stock Report

Market Cap: €68.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Exprivia Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Exprivia.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

IT earnings growth7.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article Nov 18

Exprivia (BIT:XPR) Is Doing The Right Things To Multiply Its Share Price

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analysis Article Sep 23

Is It Time To Consider Buying Exprivia S.p.A. (BIT:XPR)?

Exprivia S.p.A. ( BIT:XPR ), might not be a large cap stock, but it received a lot of attention from a substantial...
Analysis Article Aug 30

A Look At The Intrinsic Value Of Exprivia S.p.A. (BIT:XPR)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Exprivia S.p.A...
Analysis Article Aug 10

Exprivia (BIT:XPR) Shareholders Will Want The ROCE Trajectory To Continue

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
Analysis Article Jun 14

What Is Exprivia S.p.A.'s (BIT:XPR) Share Price Doing?

While Exprivia S.p.A. ( BIT:XPR ) might not be the most widely known stock at the moment, it saw a double-digit share...
Analysis Article Apr 04

Exprivia S.p.A.'s (BIT:XPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Those holding Exprivia S.p.A. ( BIT:XPR ) shares would be relieved that the share price has rebounded 28% in the last...
Analysis Article Mar 01

Does Exprivia (BIT:XPR) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Feb 02

Exprivia (BIT:XPR) Is Looking To Continue Growing Its Returns On Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Analysis Article Nov 11

Does Exprivia (BIT:XPR) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Jul 08

Exprivia (BIT:XPR) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Jun 10

Should You Investigate Exprivia S.p.A. (BIT:XPR) At €1.32?

While Exprivia S.p.A. ( BIT:XPR ) might not be the most widely known stock at the moment, it received a lot of...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Exprivia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

BIT:XPR - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2023197131417N/A
9/30/2023195132022N/A
6/30/2023186121416N/A
3/31/2023183121820N/A
12/31/2022178121214N/A
9/30/2022187111114N/A
6/30/2022184111315N/A
3/31/2022181111012N/A
12/31/2021179101619N/A
9/30/2021170102529N/A
6/30/202116893438N/A
3/31/202116682935N/A
12/31/202016493136N/A
9/30/2020-991643531N/A
6/30/2020-5783736N/A
3/31/202098773739N/A
12/31/2019165702833N/A
9/30/2019567-823046N/A
6/30/20195794-214N/A
3/31/201960782337N/A
12/31/201861501531N/A
9/30/2018473-5-75N/A
6/30/2018367-71222N/A
3/31/2018235-12-44N/A
12/31/2017160069N/A
9/30/2017153-1N/A12N/A
6/30/20171482N/A10N/A
3/31/20171444N/A8N/A
12/31/20161403N/A12N/A
9/30/20161395N/A2N/A
6/30/20161374N/A3N/A
3/31/20161394N/A-3N/A
12/31/20151415N/A-1N/A
9/30/20151464N/A11N/A
6/30/20151484N/A11N/A
3/31/20151474N/A9N/A
12/31/20141444N/A14N/A
9/30/20141373N/A7N/A
6/30/20141353N/A10N/A
3/31/20141302N/A17N/A
12/31/20131282N/A12N/A
9/30/20131313N/A15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XPR's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if XPR's earnings are forecast to grow faster than the Italian market

High Growth Earnings: Insufficient data to determine if XPR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if XPR's revenue is forecast to grow faster than the Italian market.

High Growth Revenue: Insufficient data to determine if XPR's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XPR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/18 22:55
End of Day Share Price 2024/07/16 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exprivia S.p.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea DevitaBanca Akros S.p.A. (ESN)
Laura CarmignaniIntesa Sanpaolo Equity Research